Major depressive disorder (MDD) is a debilitating psychiatric condition characterized by a persistently low mood, a lack of ...

An experimental depression drug that joined the Neurocrine Biosciences pipeline as part of a broader package from Takeda Pharmaceutical failed to meet the main goal of a mid-stage clinical trial. The ...

The largest and most ethnically diverse study of its kind has identified 697 genetic variants linked to major depressive disorder (MDD). The research also highlights potential therapies for ...

Incorporating dynamic pricing into cost-effectiveness analysis could offer significant benefits for equity in health care. The life cycle of a drug encompasses phases of market exclusivity, ...

Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response and remission The accelerated protocol is now ...

Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress BUOY-1 builds on successful ...

Patients with first-episode MDD showed lower effective and functional connectivity between the anterior cingulate cortex and frontal regions.

Neumora Therapeutics, Inc. (NMRA) is gearing up to report results from one of its phase 3 studies, which is using its drug Navacaprant for the treatment of patients with major depressive disorder (MDD ...

Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved ...

BURLINGTON, Mass. and JERUSALEM, Sept. 16, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (BWAY) (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation ...